{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-061308","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.069206+00:00","generated_at":"2026-06-27T02:51:57.556002+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Director H. Thomas Watkins to resign; executive compensation and equity grants for 2022","bullets":["H. Thomas Watkins, director since 2006, will resign at 2022 Annual Meeting; board to shrink from 6 to 5.","CEO Mihael Polymeropoulos awarded 2021 bonus of $596,744; 2022 base salary $815,140 and target bonus 80%.","2022 option grants at $11.36/share: CEO receives 275,000 options and 115,000 RSUs.","CFO Kevin Moran 2021 bonus $175,473; 2022 base $426,120 and target 45%; option for 77,500 shares.","Aranthan Jones resigned as Chief Corporate Affairs Officer effective Oct 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-061308","json":"https://secwatch.observer/filing/0001193125-22-061308.json","markdown":"https://secwatch.observer/filing/0001193125-22-061308.md","text":"https://secwatch.observer/filing/0001193125-22-061308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/0001193125-22-061308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/d287693d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:51:57.556002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90a8437350","claim":"Aranthan \"AJ\" Jones II resigned as Chief Corporate Affairs and Communications Officer at Vanda Pharmaceuticals Inc..","evidence_excerpt":"Mr. Jones resigned as the Company’s Chief Corporate Affairs and Communications Officer effective as of October 26, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/0001193125-22-061308-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Corporate Affairs and Communications Officer"}],"fact_type":"executive_change"},{"claim_id":"b6d5793d4d","claim":"H. Thomas Watkins resigned as Class I director at Vanda Pharmaceuticals Inc..","evidence_excerpt":"H. Thomas Watkins notified the Board that he would resign from the Board as a Class I director effective as of the Company’s 2022 Annual Meeting of Stockholders","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/0001193125-22-061308-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}